That includes tirzepatide and the GLP-1 RAs
In a pharmacological context, food intake is minimally impacted by interference with endogenous GLP1/GLP1 receptor, while eating is decreased by activation of GLP1 neurons within the nucleus tractus solitarius (Cheng et al., 2020
Excitotoxicity is involved in many pathological conditions, such as cerebral ischemia, epilepsy, Parkinsons disease (PD), AD, and amyotrophic lateral sclerosis (ALS) (Dingledine et al., 1999
Berberine: appears to influence metabolism largely through pathways that include AMPK (often described as an energy-regulation switch) and effects on insulin sensitivity
Nutritional solutions are increasingly required to mitigate side effects such as muscle loss, which affects over 40% of GLP-1 users
By then, we could also have a GLP-1 landscape that includes the triple-agonist injection retatrutide